Analysis of Pharmacokinetic/Pharmacodynamic Parameters and Dosage Regimen of Posaconazole against <i>Candida</i> spp. and <i>Aspergillus</i> spp. Using Monte Carlo Simulation — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Analysis of Pharmacokinetic/Pharmacodynamic Parameters and Dosage Regimen of Posaconazole against <i>Candida</i> spp. and <i>Aspergillus</i> spp. Using Monte Carlo Simulation
Department of Pharmacy, Affiliated Hospital of Chengde Medical College, Chengde, China
,
Department of Functional Center, Chengde Medical College, Chengde, China
,
Department of Pharmacy, Affiliated Hospital of Chengde Medical College, Chengde, China
,
Department of Pharmacy, Affiliated Hospital of Chengde Medical College, Chengde, China
,
Department of Pharmacy, Affiliated Hospital of Chengde Medical College, Chengde, China
1 Department of Pharmacy, Affiliated Hospital of Chengde Medical College, Chengde, China
2 Department of Functional Center, Chengde Medical College, Chengde, China
3 Department of Pharmacy, Affiliated Hospital of Chengde Medical College, Chengde, China
4 Department of Pharmacy, Affiliated Hospital of Chengde Medical College, Chengde, China
5 Department of Pharmacy, Affiliated Hospital of Chengde Medical College, Chengde, China
Invasive fungal infections (IFI) have recently become increasingly more prevalent, resulting in an increased risk of morbidity and mortality. Both Candida spp. and Aspergillus spp. are major causes of IFI. In this study, we aimed to evaluate the cumulative fraction of response of various dosage regimens of posaconazole against nine Candida spp. and six Aspergillus spp. in both children and adults. Monte Carlo simulation (MCS) was performed to optimize selection of posaconazole dosage regimens. For children, a dosage regimen of 120 mg/m 2 posaconazole tid was suff icient to treat fungal infections caused by all six Aspergillus spp. and six of the nine Candida spp. (but was not effective against C . glabrata , C . guilliermondii and C . krusei ). In contrast, a 400 mg dosage regimen of posaconazole bid achieved the target pharmacokinetic/pharmacodynamics (PK/PD) parameters against all six Aspergillus spp. and eight of the nine Candida spp. (but was not effective against C . glabrata ) in the adults. Dosage regimens of 50 mg bid, 100 mg bid, or 200 mg bid were not effective. Posaconazole dosage regimens are likely to achieve their desired PK/PD targets against Candida spp. and Aspergillus spp. in both children and adults.
KeywordsPosaconazoleMonte Carlo Simulation<i>Candida</i>spp.<i>Aspergillus</i>spp.Pharmacokinetics/Pharmacodynamics
Al-Abdely, H.M., Alothman, A.F., Salman, J.A., Al-Musawi, T., Almaslamani, M., Butt, A.A., Al Thaqafi, A.O., Raghubir, N., Morsi, W.E. and Yared, N.A. (2014) Clinical Practice Guidelines for the Treatment of Invasive Aspergillus Infections in Adults in the Middle East Region: Expert Panel Recommendations. Journal of Infection and Public Health, 7, 20-31. http://www.ncbi.nlm.nih.gov/pubmed/24029495 https://doi.org/10.1016/j.jiph.2013.08.003
Bassetti, M. and Bouza, E. (2017) Invasive Mould Infections in the ICU Setting: Complexities and Solutions. Journal of Antimicrobial Chemotherapy, 72, i39-i47. http://www.ncbi.nlm.nih.gov/pubmed/28355466 https://doi.org/10.1093/jac/dkx032
Drew, R.H., Townsend, M.L., Pound, M.W., Johnson, S.W. and Perfect, J.R. (2013) Recent Advances in the Treatment of Life-Threatening, Invasive Fungal Infections. Expert Opinion on Pharmacotherapy, 14, 2361-2374. http://www.ncbi.nlm.nih.gov/pubmed/24050675 https://doi.org/10.1517/14656566.2013.838217
Sabatelli, F., Patel, R., Mann, P.A., Mendrick, C.A., Norris, C.C., Hare, R., Loebenberg, D., Black, T.A. and McNicholas, P.M. (2006) In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts. Antimicrobial Agents and Chemotherapy, 50, 2009-2015. http://www.ncbi.nlm.nih.gov/pubmed/16723559 https://doi.org/10.1128/AAC.00163-06
Dolton, M.J., Bruggemann, R.J., Burger, D.M. and McLachlan, A.J. (2014) Understanding Variability in Posaconazole Exposure Using an Integrated Population Pharmacokinetic Analysis. Antimicrobial Agents and Chemotherapy, 58, 6879-6885. http://www.ncbi.nlm.nih.gov/pubmed/25199779 https://doi.org/10.1128/AAC.03777-14
Li, Y., Theuretzbacher, U., Clancy, C.J., Nguyen, M.H. and Derendorf, H. (2010) Pharmacokinetic/Pharmacodynamic Profile of Posaconazole. Clinical Pharmacokinetics, 49, 379-396. http://www.ncbi.nlm.nih.gov/pubmed/20481649 https://doi.org/10.2165/11319340-000000000-00000
Krishna, G., Moton, A., Ma, L., Medlock, M.M. and McLeod, J. (2009) Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 53, 958-966. http://www.ncbi.nlm.nih.gov/pubmed/19075045 https://doi.org/10.1128/AAC.01034-08
Clark, N.M., Grim, S.A. and Lynch, J.P. (2015) Posaconazole: Use in the Prophylaxis and Treatment of Fungal Infections. Seminars in Respiratory and Critical Care Medicine, 36, 767-785. http://www.ncbi.nlm.nih.gov/pubmed/26398542 https://doi.org/10.1055/s-0035-1562902
Xu, G., Zhu, L., Ge, T., Liao, S., Li, N. and Qi, F. (2016) Pharmacokinetic/Phar- macodynamic Analysis of Voriconazole against Candida spp. and Aspergillus spp. in Children, Adolescents and Adults by Monte Carlo Simulation. International Journal of Antimicrobial Agents, 47, 439-445. http://www.ncbi.nlm.nih.gov/pubmed/27179818 https://doi.org/10.1016/j.ijantimicag.2016.02.016
Koomanachai, P., Yungyuen, T., Disthaporn, P., Kiratisin, P. and Nicolau, D.P. (2016) Application of Pharmacodynamic Profiling for the Selection of Optimal Beta-Lactam Regimens in a Large University Hospital. International Journal of Infectious Diseases, 46, 22-26. http://www.ncbi.nlm.nih.gov/pubmed/27021531 https://doi.org/10.1016/j.ijid.2016.03.020
Xie, J., Wang, T., Sun, J., Chen, S., Cai, J., Zhang, W., Dong, H., Hu, S., Zhang, D., Wang, X. and Dong, Y. (2014) Optimal Tigecycline Dosage Regimen Is Urgently Needed: Results from a Pharmacokinetic/Pharmacodynamic Analysis of Tigecycline by Monte Carlo Simulation. International Journal of Infectious Diseases, 18, 62-67. http://www.ncbi.nlm.nih.gov/pubmed/24246741 https://doi.org/10.1016/j.ijid.2013.09.008
Soon, R.L., Turner, S.J., Forrest, A., Tsuji, B.T. and Brown, J. (2013) Pharmacokinetic/Pharmacodynamic Evaluation of the Efficacy and Safety of Daptomycin against Staphylococcus aureus. International Journal of Antimicrobial Agents, 42, 53-58. http://www.ncbi.nlm.nih.gov/pubmed/23684388 https://doi.org/10.1016/j.ijantimicag.2013.02.009
Canut, A., Isla, A., Betriu, C. and Gascon, A.R. (2012) Pharmacokinetic-Pharma- codynamic Evaluation of Daptomycin, Tigecycline, and Linezolid versus Vancomycin for the Treatment of MRSA Infections in Four Western European Countries. European Journal of Clinical Microbiology & Infectious Diseases, 31, 2227-2235. http://www.ncbi.nlm.nih.gov/pubmed/22371294 https://doi.org/10.1007/s10096-012-1560-7
Doan, T.N., Kong, D.C.M., Patel, K., Walker, P., Spencer, A. and Kirkpatrick, C.M.J. (2014) Comparison of the Probability of Target Attainment of Anidulafungin against Candida spp. in Patients with Acute Leukaemia. International Journal of Antimicrobial Agents, 44, 450-457. http://www.sciencedirect.com/science/article/pii/S0924857914002556 https://doi.org/10.1016/j.ijantimicag.2014.07.019
Mouton, J.W., Schmitt-Hoffmann, A., Shapiro, S., Nashed, N. and Punt, N.C. (2004) Use of Monte Carlo Simulations to Select Therapeutic Doses and Provisional Breakpoints of BAL9141. Antimicrobial Agents and Chemotherapy, 48, 1713-1718. https://www.ncbi.nlm.nih.gov/pubmed/15105125 https://doi.org/10.1128/AAC.48.5.1713-1718.2004
Xu, G., Zhu, L., Liao, S., Ge, T. and Yang, J. (2015) Assessment of Echinocandin Regimens by Pharmacokinetic/Pharmacodynamic Analysis against Candida spp. in Paediatric Patients. International Journal of Antimicrobial Agents, 46, 631-641. http://www.sciencedirect.com/science/article/pii/S0924857915003131 https://doi.org/10.1016/j.ijantimicag.2015.08.009
Courtney, R., Pai, S., Laughlin, M., Lim, J. and Batra, V. (2003) Pharmacokinetics, Safety, and Tolerability of Oral Posaconazole Administered in Single and Multiple Doses in Healthy Adults. Antimicrobial Agents and Chemotherapy, 47, 2788-2795. http://www.ncbi.nlm.nih.gov/pubmed/12936975 https://doi.org/10.1128/AAC.47.9.2788-2795.2003
Vanstraelen, K., Colita, A., Bica, A.M., Mols, R., Augustijns, P., Peersman, N., Vermeersch, P., Annaert, P. and Spriet, I. (2016) Pharmacokinetics of Posaconazole Oral Suspension in Children Dosed According to Body Surface Area. The Pediatric Infectious Disease Journal, 35, 183-188. http://www.ncbi.nlm.nih.gov/pubmed/26544987 https://doi.org/10.1097/INF.0000000000000963
Andes, D., Marchillo, K., Conklin, R., Krishna, G., Ezzet, F., Cacciapuoti, A. and Loebenberg, D. (2004) Pharmacodynamics of a New Triazole, Posaconazole, in a Murine Model of Disseminated Candidiasis. Antimicrobial Agents and Chemotherapy, 48, 137-142. http://www.ncbi.nlm.nih.gov/pubmed/14693531 https://doi.org/10.1128/AAC.48.1.137-142.2004
Lepak, A.J., Marchillo, K., Vanhecker, J. and Andes, D.R. (2013) Posaconazole Pharmacodynamic Target Determination against Wild-Type and Cyp51 Mutant Isolates of Aspergillus fumigatus in an in Vivo Model of Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 57, 579-585. http://www.ncbi.nlm.nih.gov/pubmed/23147740 ttps://doi.org/10.1128/AAC.01279-12
Liao, S., Ge, T., Zhu, L., Zhao, Y., Yang, J. and Xu, G. (2015) A Pharmacokinetic/Pharmacodynamic Analysis of a Standard Voriconazole Regimen in Different CYP2C19 Genotypes by Monte Carlo Simulation. Pharmazie, 70, 306-309. http://www.ncbi.nlm.nih.gov/pubmed/26062298
Howard, S.J., Lestner, J.M., Sharp, A., Gregson, L., Goodwin, J., Slater, J., Majithiya, J.B., Warn, P.A. and Hope, W.W. (2011) Pharmacokinetics and Pharmacodynamics of Posaconazole for Invasive Pulmonary Aspergillosis: Clinical Implications for Antifungal Therapy. The Journal of Infectious Diseases, 203, 1324-1332. http://www.ncbi.nlm.nih.gov/pubmed/21357943 https://doi.org/10.1093/infdis/jir023
Mavridou, E., Bruggemann, R.J., Melchers, W.J., Mouton, J.W. and Verweij, P.E. (2010) Efficacy of Posaconazole against Three Clinical Aspergillus fumigatus Isolates with Mutations in the cyp51A Gene. Antimicrobial Agents and Chemotherapy, 54, 860-865. http://www.ncbi.nlm.nih.gov/pubmed/19917751 https://doi.org/10.1128/AAC.00931-09
Cacciapuoti, A., Loebenberg, D., Corcoran, E., Menzel Jr., F., Moss Jr., E.L., Norris, C., Michalski, M., Raynor, K., Halpern, J., Mendrick, C., Arnold, B., Antonacci, B., Parmegiani, R., Yarosh-Tomaine, T., Miller, G.H. and Hare, R.S. (2000) In Vitro and in Vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, against Aspergillus and Candida. Antimicrobial Agents and Chemotherapy, 44, 2017-2022. http://www.ncbi.nlm.nih.gov/pubmed/10898669 https://doi.org/10.1128/AAC.44.8.2017-2022.2000
Graybill, J.R., Bocanegra, R., Najvar, L.K., Luther, M.F. and Loebenberg, D. (1998) SCH56592 Treatment of Murine Invasive Aspergillosis. Journal of Antimicrobial Chemotherapy, 42, 539-542. http://www.ncbi.nlm.nih.gov/pubmed/9818757 https://doi.org/10.1093/jac/42.4.539
Groll, A.H. and Lehrnbecher, T. (2008) Posaconazole for Paediatric Patients: Status of Development and Future Perspectives. Mycoses, 51, 5-11. http://www.ncbi.nlm.nih.gov/pubmed/18721328 https://doi.org/10.1111/j.1439-0507.2008.01569.x
Jones, R.N., Craig, W.A., Ambrose, P.G., Dudley, M.N. and Pottumarthy, S. (2005) Reevaluation of Enterobacteriaceae MIC/Disk Diffusion Zone Diameter Regression Scattergrams for 9 Beta-Lactams: Adjustments of Breakpoints for Strains Producing Extended Spectrum Beta-Lactamases. Diagnostic Microbiology and Infectious Disease, 52, 235-246. http://www.ncbi.nlm.nih.gov/pubmed/16105568 https://doi.org/10.1016/j.diagmicrobio.2005.02.006